Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT02729025

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02729025
  • EudraCT 2015-003731-35
Other papers using this trial's data
  • Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a) Lipids in health and disease, 2020-05-11 DOI, PubMed 32393252, PMC7216641 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02729025. Randomized; triple masking; primary purpose treatment. Start 2016-04-14 (actual); primary completion 2018-04-05 (actual). Results posted on 2019-04-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Acronym
ANITSCHKOW
Condition
Subjects With Hyperlipidemia, Dyslipidemia
Intervention (Drug)
Evolocumab
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02729025
Content hash
ab7c59506cf414764ff825e98df6dae63c85fa58db97b73d137e9f40186c4116